复星医药
(600196)
| 流通市值：476.87亿 | | | 总市值：601.56亿 |
| 流通股本：21.18亿 | | | 总股本：26.72亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 41,399,539,588.42 | 30,700,119,056.12 | 21,395,192,579.88 | 10,870,720,838.66 |
| 营业收入 | 41,399,539,588.42 | 30,700,119,056.12 | 21,395,192,579.88 | 10,870,720,838.66 |
| 二、营业总成本 | 41,284,076,914.38 | 30,284,279,170.47 | 20,632,041,911.73 | 10,098,284,416.33 |
| 营业成本 | 21,595,308,756.94 | 15,779,521,220.28 | 10,698,520,459.19 | 5,294,793,592.4 |
| 税金及附加 | 271,255,381.04 | 197,962,111.28 | 137,573,015.85 | 67,021,438.49 |
| 销售费用 | 9,712,237,437.28 | 7,226,681,929.85 | 5,071,295,590.41 | 2,515,248,697.15 |
| 管理费用 | 4,374,907,225.8 | 3,168,933,375.04 | 2,045,007,621.27 | 991,092,476.64 |
| 研发费用 | 4,346,044,722.61 | 3,155,101,729.15 | 2,134,278,692.35 | 968,872,153.04 |
| 财务费用 | 984,323,390.71 | 756,078,804.87 | 545,366,532.66 | 261,256,058.61 |
| 其中:利息费用 | 1,324,830,525.62 | 947,670,221.32 | 603,375,435.37 | 285,006,358.32 |
| 其中:利息收入 | 363,645,386.22 | 265,614,789.02 | 171,493,763.87 | 90,124,875.29 |
| 加:公允价值变动收益 | -427,379,582.37 | 806,336,386.57 | 387,373,858.95 | -147,606,069.58 |
| 加:投资收益 | 3,501,992,600.27 | 2,182,417,314.63 | 1,473,380,689.52 | 765,904,456.45 |
| 资产处置收益 | 5,563,773.63 | 6,299,669.38 | 804,989.09 | -507,677.32 |
| 资产减值损失(新) | -219,742,228.92 | -290,902,742.88 | -91,659,781.06 | -13,184,652.04 |
| 信用减值损失(新) | -131,927,327.75 | -81,582,526.65 | -57,975,516.32 | -12,412,702.93 |
| 其他收益 | 463,537,996.22 | 303,789,784.16 | 207,535,848.91 | 62,509,515.5 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 3,307,507,905.12 | 3,342,197,770.86 | 2,682,610,757.24 | 1,427,139,292.41 |
| 加:营业外收入 | 57,124,008.22 | 49,590,722.66 | 24,205,889.19 | 5,623,655.93 |
| 减:营业外支出 | 100,064,034.6 | 99,332,003.91 | 51,346,675.26 | 47,998,916.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,264,567,878.74 | 3,292,456,489.61 | 2,655,469,971.17 | 1,384,764,032.27 |
| 减:所得税费用 | 369,504,452.16 | 638,646,952.94 | 610,244,692.73 | 270,509,922.11 |
| 六、净利润 | 2,895,063,426.58 | 2,653,809,536.67 | 2,045,225,278.44 | 1,114,254,110.16 |
| 持续经营净利润 | 2,895,063,426.58 | 2,653,809,536.67 | 2,045,225,278.44 | 1,114,254,110.16 |
| 归属于母公司股东的净利润 | 2,386,265,813.74 | 2,283,065,930.63 | 1,777,471,869.71 | 986,971,662.49 |
| 少数股东损益 | 508,797,612.84 | 370,743,606.04 | 267,753,408.73 | 127,282,447.67 |
| (一)基本每股收益 | 0.89 | 0.86 | 0.67 | 0.37 |
| (二)稀释每股收益 | 0.89 | 0.85 | 0.67 | 0.37 |
| 八、其他综合收益 | 31,857,159.28 | 383,047,217.57 | 475,605,847.37 | -183,486,478.67 |
| 归属于母公司股东的其他综合收益 | -35,442,050.43 | 219,204,955.15 | 258,822,963.42 | -152,600,408.1 |
| 九、综合收益总额 | 2,926,920,585.86 | 3,036,856,754.24 | 2,520,831,125.81 | 930,767,631.49 |
| 归属于母公司股东的综合收益总额 | 2,350,823,763.31 | 2,502,270,885.78 | 2,036,294,833.13 | 834,371,254.39 |
| 归属于少数股东的综合收益总额 | 576,096,822.55 | 534,585,868.46 | 484,536,292.68 | 96,396,377.1 |
| 公告日期 | 2024-03-27 | 2023-10-31 | 2023-08-30 | 2023-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |